New treatment for aggressive breast cancer has 100% survival rate

Hope is on the horizon for patients with aggressive, inherited breast cancers.

A recent clinical test, led by researchers at the University of Cambridge, explored the effects of combining chemotherapy with the target Olaparib cancer drug before surgery.

The patient who received this protocol survived the three-year critical period after treatment.

The research, published in Nature Communications, suggests that this prejudicial approach, with two parts, may be the most effective treatment plan for early stage breast cancer associated with BRCA1 and BrCa2 gene mutations.

Breast cancer or BRCA genes are present in every cell of the human body. When working, BRCA1 and BRCA2 repair DNA and prevent cancerous changes.

However, when a mutation endangers these genes, the risk of cancer increases. The legacy of this damaged DNA can increase the risk of breast and ovarian cancer in women and breast and prostate cancer in men.

BRCA1 or BRCA2 genes are more common in young women, and these mutations increase the risk of cancer by up to 84%. Six percent of all patients with breast cancer maintain mutations in the BRCA gene, but in patients under 45, approximately 12% hold the gene.

BRCA cancers are extremely aggressive and difficult to treat.

In 2013, Angelina Jolie, who carries the wrong BRCA1 gene, made titles when she underwent a double preventive mastectomy. As a result of the procedure, Jolie, who lost her mother in breast cancer, saw her chances of developing breast cancer from 87 percent to less than 5 percent.

The current BRCA cancer treatment protocol involves shrinking the tumor using chemotherapy and immunotherapy before removing it through surgery.

The first three years after surgery – when there is the greatest risk of relapse or death – they are critical.

The trial recruited patients from all over the United Kingdom and intended to test the efficiency of combining chemotherapy with Olaparib BEFORE Surgery and time carefully when these treatments were administered.

“It is rare to have a 100% survival scale in a study like this and for these aggressive types of cancer.”

Professor Jean Abraham

The study found that allowing a 48-hour “gap” between chemotherapy and Olaparib treatments led to more positive results. Researchers believe that this interval allows the patient’s bone marrow to heal from chemistry while leaving tumor cells acceptable in Olaparib.

Olaparib, sold under the brand Lynparza, is usually taken for 12 months after surgery. However, patients with trial took pre -surgery tablets for a period of 12 weeks.

The survival rate among the control group that received only chemotherapy was 88%. Of these 45 patients, nine relaxed and six died within three years of surgery.

In contrast, there was a 100% survival rate among the 39 patients who received chemotherapy followed by Olaparib. From this group, only one patient withdrew in three years after surgery.

“It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer,” said Jean Abraham’s leading judgment professor.

“We are very excited about the potential of this new approach, as it is important to find a way to treat and hope to cure patients who are diagnosed with BRCA1 and BRCA2 cancers.”

Compared to current care protocols, two-way access to chemioito and pre-surgery olaparib offers a more cost-effective and less toxic treatment for patients.

Abrahams and his team are planning the next phase of research, which will aim to repeat their results in a larger study.

They are hopeful that their findings can and will be applied to treat other cancers caused by mutated BRCA genes, including some ovarian, prostate and pancreatic cancers.

Breast cancer is the most common cancer among American women after skin cancer. About 1 in 8 women will be diagnosed with breast cancer during their lifetime.

Although breast cancer begins in a localized part of the breast tissue, it can spread to other areas of the body, significantly reducing survival rates.

The survival rate among patients with breast cancer, whose cancer is detected before spreading are high, between 86% and 89%. However, if cancer is detected after cancer cells have migrated, it drops to 31%.